SMARCB1 and cancer: In addition, enhancer of zeste homolog 2 (EZH2) inhibitors are new drugs for the treatment of cancers lacking SMARCB1, and preclinical studies have shown that they have the potential to modulate tumor immunogenicity and antitumor immune responses (57).